This study is testing a new medicine, **CLE-100** (also called oral esketamine), for people with Major Depressive Disorder (MDD) who do not respond well to regular antidepressants. MDD is a condition where a person feels very sad or hopeless for a long time. The study wants to see if CLE-100 can help when taken with their usual medicine. Participants will take CLE-100 or a placebo (looks like the medicine but isn’t) once a day for 4 weeks. If they complete this part and qualify, they can continue taking CLE-100 for 6 more months.
NCT06340958
Clexio Biosciences Ltd.
8 July 2024
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Congrats! You have your own personal workspace now.